Transient hyperprolactinaemia in human menopausal gonadotropin induction of ovulation.
In 20 anovulatory patients who were normoprolactinaemic, 12 developed transient hyperprolactinaemia when they were treated with human menopausal gonadotropin (hMG) for induction of ovulation. The hyperprolactinaemia was probably due to the increased oestrogen production effect on some susceptible patients. The pregnancy rate was found to be lower in those who developed this condition. The dosage of hMG required was found to be significantly higher in this group. The importance of recognizing this transient hyperprolactinaemia and the probably role of Bromocriptine are discussed. Further study is suggested.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use*; D008599:Menstruation Disturbances / Q000188:drug therapy*; D009839:Oligomenorrhea / Q000188:drug therapy*; D010062:Ovulation Induction; D011388:Prolactin / Q000097:blood*; D013997:Time Factors
D004958:Estradiol; D008596:Menotropins; D011388:Prolactin